SCHEMBL3963003

SCHEMBL3963003

O=C(CCl)N(Cc1ccc(Cl)cc1)Cc1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.68
HTT P42858 4/20 0.68
RAB9A P51151 3/20 0.68
YAP1 P46937 1/20 0.49
TEAD4 Q15561 1/20 0.49
TEAD2 Q15562 1/20 0.49
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
POLB P06746 2/20 0.45
GSK3B P49841 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
GLA P06280 1/20 0.44
PAX8 Q06710 1/20 0.44
KDM4E B2RXH2 2/20 0.44
CNR2 P34972 2/20 0.43
MITF O75030 1/20 0.43
BCL2A1 Q16548 1/20 0.43
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963919 0.88 ALDH1A1 (0.59) ALDH1A1HTTRAB9AYAP1TEAD4
SCHEMBL3964939 0.87 RAB9A (0.58) ALDH1A1HTTRAB9AYAP1TEAD4
SCHEMBL3965065 0.87 ALDH1A1 (0.54) ALDH1A1HTTRAB9AYAP1TEAD4
SCHEMBL5451636 0.82 NPC1 (0.67) ALDH1A1HTTRAB9AMEN1KMT2A
SCHEMBL9824635 0.81 ALDH1A1 (1.00) ALDH1A1HTTRAB9AMEN1KMT2A
SCHEMBL3967969 0.80 GAA (0.51) ALDH1A1HTTRAB9AYAP1TEAD4
SCHEMBL6122081 0.79 ALDH1A1 (0.52) ALDH1A1HTTRAB9AMEN1KMT2A
SCHEMBL3959677 0.78 YAP1 (0.48) ALDH1A1HTTRAB9AYAP1TEAD4
SCHEMBL8668663 0.78 NPC1 (0.53) ALDH1A1HTTRAB9AMEN1KMT2A
SCHEMBL8671700 0.78 RAB9A (0.49) ALDH1A1HTTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US disclosed
US-20070244198-A1 Carboxylic Derivatives LI LANNA 2007-10-18 US disclosed
US-20060258866-A1 Carboxylic derivates ASTRAZENECA AB, A SWEDEN CORPORATION 2006-11-16 US disclosed
EP-1675820-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS AstraZeneca AB (SE) 2006-07-05 EP disclosed
EP-1676833-A1 Propionic acid derivatives useful in the treatment of lipid disorders AstraZeneca AB (SE) 2006-07-05 EP disclosed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US disclosed
US-20050148656-A1 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes ASTRAZENECA AB (SE) 2005-07-07 US disclosed
WO-2004113270-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244198-A1 Carboxylic Derivatives GPR119, CPT1A, PC ALDH1A1 323/4885HTT 3936/4885RAB9A 2041/4885
US-20050148656-A1 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes GPR119, PPARA, PPARG ALDH1A1 1343/4885HTT 4094/4885RAB9A 2433/4885
US-20060258866-A1 Carboxylic derivates GPR119, PC, CPT1A ALDH1A1 230/4885HTT 3674/4885RAB9A 2015/4885
US-20050282822-A1 Therapeutic agents GPR119, LIPC, PNLIP ALDH1A1 1921/4885HTT 3393/4885RAB9A 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.